AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus surged after securing up to $340M in financing to fund its Phase III ROBBIN colon cancer study and extend its cash runway, with additional runway supported if warrants are exercised. The update reduces near-term funding risk while keeping the Phase III program on track.

Analysis

Agenus surged after securing up to $340M in financing to fund its Phase III ROBBIN colon cancer study and extend its cash runway, with additional runway supported if warrants are exercised. The update reduces near-term funding risk while keeping the Phase III program on track.